The first mechanistic connection between p53 and Bcl-2 came from the identification of the proapoptotic ‘multi-domain’ Bcl-2 family member Bax, initially identified by the Korsmeyer laboratory ...

p53 was not correlated to any patient or tumor characteristic, whereas bcl-2 showed higher expression in squamous cell carcinomas (P < .001). bax expression was significantly related with male sex (P ...

Frequent expression of p53, mdm2, and bcl-2 proteins was found in the cervical lesions. However, only p53 expression independently provided information for prediction of the clinical course of HPV ...

[4,7,8] The p53 protein binds to members of the Bcl-2 family, increasing mitochondrial permeability and the release of mitochondrial intermembrane molecules that trigger downstream apoptotic events.

The company has built a rich pipeline of innovative drug candidates that includes inhibitors targeting key proteins in the apoptotic pathway, such as Bcl-2 and MDM2-p53 and next-generation kinase ...

The following is a summary of “ER-α36 prevents high glucose-induced cellular senescence and apoptosis in renal tubular cell,” ...

Dublin, March 15, 2023 (GLOBE NEWSWIRE) -- The "Global BCL-2 (B-cell lymphoma 2) Inhibitors Market 2023-2027" report has been added to ResearchAndMarkets.com's offering.The BCL-2 (B-cell Lymphoma ...

Lisaftoclax is a novel Bcl-2 inhibitor developed by Ascentage Pharma. In November 2024, the New Drug Application (NDA) for lisaftoclax for the treatment of R/R chronic lymphocytic leukemia/small ...

Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855) is a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers. The company has built a rich pipeline of innovative drug ...

Detailed price information for Ascentage Pharma Group Intl ADR (AAPG-Q) from The Globe and Mail including charting and trades.